FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF C	HANGES	S IN BE	NEFICIAL	OWNERS	SHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average	burden							
hours per response	: 0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Thompson Peter A.				2. Issuer Name <b>and</b> Ticker or Trading Symbol Silverback Therapeutics, Inc. [SBTX]						(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director X 10% Owner				ner	
(Last) (First) (Middle) C/O SILVERBACK THERAPEUTICS, INC.				3. Date of Earliest Transaction (Month/Day/Year) 06/10/2022							Officer below)	(give title		Other (s below)	pecify	
500 FAIRVIEW AVENUE N, SUITE 600			4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) SEATTL	E W	Ά	98109								- 1	X Form f	led by One led by More	•	•	
(City)	(Si	tate)	(Zip)													
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																
Date			Transactior te onth/Day/Yo	Execution Date,		Code (Inst	Transaction Disposed Of (D) (Instr. 3, Code (Instr. 5)			5. Amour Securitie Beneficia Owned F Reported	Form Sollowing (I) (In		n: Direct or Indirect Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code V	Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			mst. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, Courity or Exercise (Month/Day/Year) if any		Code (	nsaction de (Instr.  5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$4.18	06/10/2022		A		18,000		(1)	06/09/2032	Common Stock	18,000	\$0.00	18,000		D <sup>(2)</sup>	

## **Explanation of Responses:**

- 1. The shares subject to the option vest on the earlier of June 10, 2023 or the date of the Issuer's 2023 annual meeting of stockholders, which date has not been set by the Issuer's Board of Directors.
- 2. Pursuant to an agreement with OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof, to OrbiMed Advisors LLC and OrbiMed Capital GP VI LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments VI,

## Remarks:

/s/ Jeffrey C. Pepe, Attorney-in-

06/13/2022

Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.